180P - Immunotherapy as an effective therapy approach for advanced non-small cell lung cancer (NSCLC): A single institution experience in the context of c...

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Immunotherapy
Non-Small Cell Lung Cancer
Presenter Julia Martínez Pérez
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors J. Martínez Pérez1, A. Falcón González1, I. Sánchez Simón1, A. Cervera1, M. Alonso García1, M.J. Flor Oncala1, P. Maíquez2, I. Gallego Jiménez1, L. Jiménez González-Serna2, J. Corral1
  • 1Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 2Phase I Unit, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES



Lung cancer is the leading cause of cancer-related mortality globally with a 5-year survival rate 


Retrospective analysis of 61 patients with pretreated advanced NSCLC received anti-PD1 (programed cell death 1) and anti-PDL1 (programmed cell death-ligand 1) checkpoints inhibitors as expanded access treatment or as clinical trial therapy in our institution between 2013 and2015.


61 patients were identified through an institutional therapy registry, including 80.3% males with a median age of 64 (range 35–85), 50.8% squamous histology and 9.8% never-smoker patients. Mutation profile was defined as negative EGFR/ALK in 95%; unknown PDL1 in 67.2% and positive PDL1 by inmunochemistry in 19 patients (31.1%). 63.9% of patients received anti-PD1 therapy vs 36.1% anti-PDL1 immune checkpoint inhibitors; 41% of patients received immunotherapy agents after two previous chemotherapy lines and 22.9% after 3 or more. With a median follow-up of 24 months (7–90.1), only ex- or active smokers had response to immunotherapy with an overall rate of 6.6% and disease control rate of 52.5% according to RECIST 1.1. No differences were seen between lines of therapy or immunotherapy strategies, but most of patients (51%) remain on treatment so survival rate were not reached. The most common grade I-II adverse events were fatigue (59%) and anorexia (23%) and pneumonitis grade III was observed in 16.4%.


Our data are consistent with recent immunotherapy results showing high disease control rate and durable clinical responses regardless of PDL1 status, PD-1/PDL-1 inhibition or line of therapy used, with manageable toxicity.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.